The origin of MDMA ("ecstasy")--separating the facts from the myth.
Level 5 - mechanism / opinion, no new human data
Historical archive analysis (graded by design analogy, not clinical CEBM)
What was done
An interdisciplinary research group analyzed original laboratory journals, patent certificates, and historical files from Merck's company archives in Darmstadt, Germany, to investigate the circumstances surrounding the discovery and early testing of MDMA.
What was found
Archival documents revealed MDMA was first documented in 1912 under the name "Methylsafrylamin" in patent records designed to protect an alternative synthesis route for the styptic compound hydrastinine, not an anorectic. MDMA was solely an intermediate precursor. Pharmacological testing under the name "Safrylmethylamin" began in 1927 and was stopped for economic reasons; basic toxicology was conducted in the 1950s, but Merck never tested MDMA in humans. The abstract reports no quantitative data.
Why it matters
This work clarifies the historical record by disproving the widespread claim that MDMA was initially developed or patented as an appetite suppressant.
Limits
The study is a descriptive historical archive review reliant entirely on surviving corporate documents from a single company, containing no clinical or modern pharmacological data.
Cited by
- supports MDMA was originally developed by the pharmaceutical company Merck.